Pramipexole companion diagnostic - Chase Therapeutics
Latest Information Update: 01 Nov 2021
At a glance
- Originator Chase Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 22 Oct 2021 Pramipexole companion diagnostic - Chase Therapeutics is available for licensing as of 22 Oct 2021. http://www.chasetherapeutics.com/partnering/
- 21 Oct 2021 Early research in Parkinson's disease (Diagnosis) in USA (unspecified route)
- 21 Oct 2021 Chase Therapeutics plans a phase III trials in Parkinsons Disease (Diagnosis)